Sylvia Arrau Barra

Dr. Sylvia Arrau Barra

Science and Health, Universidad Mayor, Santiago, Región Metropolitana, Chile
orcid
Phd Pharmaceutical Sciences and Medical veterinary Doctor

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Sylvia Arrau BarraSylvia Arrau Barra
Sylvia Arrau Barra
CDCarla Delporte
Carla Delporte
CCCarlos Cartagena
Carlos Cartagena
MRMaité Rodríguez-Díaz
Maité Rodríguez-Díaz
PGPatricia González
Patricia González
HMHugo F. Miranda
Hugo F. Miranda

1 September 2008 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NBNadine Backhouse
Nadine Backhouse
CDCarla Delporte
Carla Delporte
CACecia Apablaza
Cecia Apablaza
MFMariela Farías
Mariela Farías
LGLeón Goïty
León Goïty
HMHugo Miranda
Hugo Miranda

25 July 2019 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Sylvia Arrau BarraSylvia Arrau Barra
Sylvia Arrau Barra
MRMaité Rodríguez-Díaz
Maité Rodríguez-Díaz
BCBruce K. Cassels
Bruce K. Cassels
GVGabriela Valenzuela-Barra
Gabriela Valenzuela-Barra
CDCarla Delporte
Carla Delporte
HMHugo F. Miranda
Hugo F. Miranda
Background: Quillaja saponaria Mol. bark contains a high concentration of triterpene saponins that have been used for centuries as a cleansing, antiinflammatory and analgesic agent in Chilean folk medicine. In earlier studies, in mice, both the anti-inflammatory as well as the antinociceptive effect of the major sapogenin, quillaic acid have been demonstrated (QA). Objective: To determine the antihyperalgesic effect of QA one and seven days after itpl administration of complete Freund's adjuvant (CFA) in male mice using the hot plate test in the presence of complete Freund's adjuvant (HP/CFA) as an acute and chronic skeletal muscle pain model. Methods: The present study evaluated the antihyperalgesic activity of QA against acute and chronic skeletal muscle pain models in mice using the hot plate test in the presence of complete Freund's adjuvant (HP/CFA), at 24 h (acute assay) and 7 days (chronic assay) , with dexketoprofen (DEX) as the reference drug. Results: In acute and chronic skeletal muscle pain assays, QA at 30 mg/kg ip elicited its maximal antihyperalgesic effects (65.0% and 53.4%) at 24 h and 7 days, respectively. The maximal effect of DEX (99.0 and 94.1 at 24 h and 7 days, respectively) was induced at 100 mg/kg. Conclusion: QA and DEX elicit dose-dependent antihyperalgesic effects against acute and chronic skeletal muscle pain, but QA is more potent than DEX in the early and late periods of inflammatory pain induced by CFA.

29 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BTBenjamin Escobar Torres
Benjamin Escobar Torres
MEMaria Teresa Silva Elgueta
Maria Teresa Silva Elgueta
ASAlexander Navarro Soto
Alexander Navarro Soto
EAEstephanie Suarez Araya
Estephanie Suarez Araya
MCMartin Sandoval Contreras
Martin Sandoval Contreras
Sylvia Arrau BarraSylvia Arrau Barra
Sylvia Arrau Barra
Chronic osteoarthritis (COA) is a degenerative and progressive disease that causes inflammation and joint pain. Conventional treatment usually includes the use of drugs, which can cause significant adverse reactions, tolerance development, and limited analgesic efficacy. In recent years, the growing interest in the endocannabinoid system (ECS) has highlighted its potential as a therapeutic option for managing pain associated with COA. This study evaluated the efficacy of twice-daily (BID) oral administration of a full-spectrum Cannabis sativa oil extract for pain management over a six-week period. Three randomized study groups were formed: Cannabis, Placebo, and Control. Participants received one of the proposed treatment protocols and underwent initial evaluations, followed by pain monitoring using the Canine Brief Pain Inventory (CBPI) and the Canine Osteoarthritis Staging Tool (COAST). In the Cannabis and Placebo groups, the study was randomized and double-blind. The Cannabis extract had a concentration of 46.4 mg/ml, including cannabidiolic acid (CBDA), cannabidiol (CBD), Δ-9 tetrahidrocannabinol (THC), and tetrahydronannabinolic acid (THCA). Both groups followed a dose-escalation protocol of 0.1 mg/kg every four days during the first four weeks, concluding with two weeks at the maximum tolerated dose (DMT) of 2 mg/kg. Patients did not experience any adverse reactions. A significant pain response was obtained on day 28 of treatment, when the dose reached 2 mg/kg (DMT), the maximum dosage at which patients felt comfortable. Canine Breaf Pain Inventory (CBPI), scale results revealed a reduction in pain from time 0 to day 28 of 39.6% in the Cannabis group, 24.7% in the Placebo group, and an increase of 1.6% in the Control group. Additionally, Canine Ostheoarthritis Staging Tool (COAST), evaluation analysis indicated a reduction from level 5 to level 4 in 55.5% of cases in the Cannabis group, while no changes were observed in the Placebo and Control groups. We proposed that the total oily extract of the Cannabis sativa plant, administered by the oral route is effective in controlling the pain associated with COA in dogs, thereby improving the quality of life of the patient, our results supported it.

13 March 2026 in Animals
Verified
Journal Article
Open access
PDF file
BTBenjamin Ignacio Escobar Torres
Benjamin Ignacio Escobar Torres
MEMaria Teresa Silva Elgueta
Maria Teresa Silva Elgueta
NANavarro Soto Alexander
Navarro Soto Alexander
SSSuárez Araya Stephanie
Suárez Araya Stephanie
SMSandoval Contreras Martín
Sandoval Contreras Martín
Sylvia Arrau BarraSylvia Arrau Barra
Sylvia Arrau Barra
Chronic osteoarthritis (COA) is a progressive and degenerative condition that causes joint inflammation and pain, often requiring long-term pharmacological management. Conventional treatments may lead to adverse effects, tolerance, and limited analgesic efficacy. This randomized, double-blind clinical trial evaluated the analgesic potential of a full-spectrum Cannabis sativa oil extract administered orally twice daily over six weeks in dogs with COA. Subjects were assigned to three groups: Cannabis, Placebo, and Control. Pain was assessed using the Canine Brief Pain Inventory (CBPI) and the Canine Osteoarthritis Staging Tool (COAST), which ranges from 0 to 4. The Cannabis extract (46.4 mg/mL) total cannabinoids: Cannabidiol (CBD), Cannabidiolic acid (CBDA), Delta-9-Tetrahydrocannabinol (Δ9-THC), and Tetrahydrocannabinolic acid (THCA), were administered using a cautious dose escalation protocol. Treatment began at ~0.1 mg/kg every 12 h, increasing by one drop (1.16 mg) every 72 h. This gradual titration continued until reaching the maximum tolerated dose (2 mg/kg every 12 h), which was maintained for the final two weeks. The protocol was designed to minimize adverse effects and allow close monitoring, especially in geriatric or clinically fragile dogs. By day 28, when the DMT was reached, the Cannabis group showed a 39.6% reduction in CBPI scores, compared to 24.7% in the Placebo group and a 1.6% increase in the Control group. COAST scores improved from level 4 to level 3 in 55.5% of dogs in the Cannabis group, with no changes observed in the other groups. We hypothesize that the co-administration of carprofen, meloxicam, or pregabalin with a full-spectrum Cannabis sativa extract—rich in acidic cannabinoids and terpenes—enhances pain relief and mobility in dogs with COA more effectively than conventional therapies alone. This study aimed to assess the efficacy of an oily full-spectrum Cannabis sativa extract as an adjunctive treatment to NSAIDs in twenty-seven dogs diagnosed with COA, and to compare pain intensity across three treatments groups.

8 October 2025 in Cuadernos Médico Sociales
Verified
Journal Article
Open access
PDF file
Sylvia Arrau BarraSylvia Arrau Barra
Sylvia Arrau Barra
Se presenta el caso de un gato con lesiones despigmentadas en cara y pabellones auriculares, diagnosticado mediante biopsia con carcinoma espinocelular superficial. Esta neoplasia, común en felinos, se asocia a exposición prolongada a rayos UV y factores genéticos. El tratamiento quirúrgico suele indicarse en casos avanzados, pero implica riesgos en pacientes geriátricos. En este caso, se optó por una terapia multimodal con meloxicam, gabapentina y cannabidiol (CBD) al 2 % en gotas orales y tópicas. En cuatro meses, se logró resolución completa de las lesiones sin recidivas. El uso de CBD se fundamenta en sus efectos antitumorales, antiinflamatorios y analgésicos, con acción sinérgica junto a AINEs.